Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery
Safety and Efficacy of Preoperative Administration of Heparin as Thromboprophylaxis in Major Thoracic Surgery
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
Study Contact
- Name: Yi-Dan Lin, MD
- Phone Number: +86 18980602136
- Email: hanyudeng@stu.scu.edu.cn
Study Contact Backup
- Name: Han-Yu Deng, MD
- Phone Number: +86 18200295920
- Email: 907151184@qq.com
Study Locations
-
-
Sichuan
-
Chengdu, Sichuan, China, 610041
- Recruiting
- Department of thoracic surgery, west china hospital, sichuan university
-
Contact:
- Han-Yu Deng, MD
- Phone Number: +86 18200295920
- Email: 907151184@qq.com
-
Principal Investigator:
- Yi-Dan Lin, MD
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 18-75 years old without any preoperative VTEs;
- patients undergoing major thoracic surgery (including lobectomy, esophagectomy, and thymectomy).
Exclusion Criteria:
- patients with coagulation disorders: preoperative international normalized ratio (INR) > 1.5, or blood platelet count < 50x10^9/L;
- patients receiving any therapeutic anticoagulation preoperatively;
- patients with severe renal or liver dysfunction.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: case group
start heparin sodium (5000IU, BID) upon admission, and continue until discharge
|
|
|
Active Comparator: control group
start heparin sodium (5000 IU,BID) from postoperative day 1, and continue until discharge
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
intraoperative bleeding volume (ml)
Time Frame: the bleeding volume (ml) during operation in the operation room for all patients
|
During the operation, the blood loss of each patient was collected and measured, and recorded by the investigators.
|
the bleeding volume (ml) during operation in the operation room for all patients
|
|
chest tube drainage volume (ml)
Time Frame: from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
|
from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
|
|
|
thromboembolism occurence rate (%)
Time Frame: within 30 days after surgery
|
within 30 days after surgery
|
|
|
APTT (s)
Time Frame: on postoperative day 1 for both group
|
on postoperative day 1 for both group
|
|
|
PT(s)
Time Frame: on postoperative day 1 for both group
|
on postoperative day 1 for both group
|
|
|
INR
Time Frame: on postoperative day 1 for both group
|
on postoperative day 1 for both group
|
|
|
blood platlet count(/L)
Time Frame: on postoperative day 1 for both group
|
on postoperative day 1 for both group
|
|
|
chest tube drainage duration (days)
Time Frame: from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
|
from postoperative day 1 to chest tube remove(usually on postoperative day 3 for lobectomy or thymectomy,on postoperative day 7 for esophagectomy )
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
PT(s)
Time Frame: rightly upon hospital admission day
|
rightly upon hospital admission day
|
|
APTT(s)
Time Frame: rightly upon hospital admission day
|
rightly upon hospital admission day
|
|
INR
Time Frame: rightly upon hospital admission day
|
rightly upon hospital admission day
|
|
blood platlet count(/L)
Time Frame: rightly upon hospital admission day
|
rightly upon hospital admission day
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WCH-20160601
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.